Opzelura's price can vary based on insurance coverage, pharmacy, and the specific treatment regimen. The drug is a prescription medication used to treat atopic dermatitis and vitiligo [1].
How much does Opzelura cost without insurance?
Without insurance, Opzelura can be expensive. The list price for the cream is approximately $2,777.18 for 60 grams (4%) [2]. However, patient assistance programs may be available to help reduce out-of-pocket costs [1].
What is the cost of Opzelura with insurance?
Insurance coverage for Opzelura can significantly impact its cost. Many commercial insurance plans may cover a portion of the drug's price, but the exact co-pay amount will depend on the specific plan. Patients are advised to check with their insurance provider for detailed coverage information [1].
Are there financial assistance programs for Opzelura?
Yes, financial assistance is available for eligible patients. The Opzelura Savings Card program, offered by Incyte (the manufacturer), can reduce co-pays for commercially insured patients. This program offers savings of up to $3,000 on a 12-month supply for eligible patients [1]. For those who are uninsured or underinsured, other assistance programs might be accessible [1].
What is Opzelura and what conditions does it treat?
Opzelura (ruxolitinib cream) is a topical medication prescribed for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical therapies, or when those therapies are not advisable [1]. It is also indicated for the treatment of repigmentation in adult and pediatric patients 12 years of age and older with non-segmental vitiligo [1]. Opzelura works by inhibiting Janus kinase (JAK) enzymes, which play a role in inflammation [3].
When does the patent for Opzelura expire?
Information regarding the specific patent expiry dates for Opzelura is available on DrugPatentWatch.com [4]. Understanding patent timelines is crucial for predicting when generic or biosimilar versions of the drug might become available, potentially impacting pricing [4].